[{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SRF617","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Surface Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Surface Oncology"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SRF231","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"SRF813","moa":"PVRIG","graph1":"Oncology","graph2":"IND Enabling","graph3":"Surface Oncology","amount2":0.81999999999999995,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.81999999999999995,"dosageForm":"","sponsorNew":"Surface Oncology \/ GlaxoSmithKline","highestDevelopmentStatusID":"5","companyTruncated":"Surface Oncology \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"IL-27","graph1":"Oncology","graph2":"IND Enabling","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Surface Oncology","highestDevelopmentStatusID":"5","companyTruncated":"Surface Oncology \/ Surface Oncology"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27 antibody","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Dostarlimab","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0.81999999999999995,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.81999999999999995,"dosageForm":"","sponsorNew":"Surface Oncology \/ GlaxoSmithKline","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-27","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Roche"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-27","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"VIB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ VIB","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ VIB"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SRF114","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Coherus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Coherus Biosciences"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Coherus BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Coherus BioSciences"}]

Find Clinical Drug Pipeline Developments & Deals by Surface Oncology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The acquisition advances Coherus' immuno-oncology pipeline by adding two clinical stage assets, SRF388 (casdozokitug), a novel IL-27-targeted antibody being evaluated in Phase 2 in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody for ad...

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : $26.9 million

                          September 08, 2023

                          Lead Product(s) : Casdozokitug,Atezolizumab,Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Coherus Biosciences

                          Deal Size : $66.9 million

                          Deal Type : Acquisition

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The acquisition advances Coherus' immuno-oncology pipeline by adding two clinical stage assets, SRF388, a novel IL-27-targeted antibody being evaluated in Phase 2 trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody for advanced s...

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : $25.0 million

                          June 16, 2023

                          Lead Product(s) : SRF388,Atezolizumab,Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Coherus Biosciences

                          Deal Size : $65.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SRF114 is a fully human, afucosylated anti-CCR8 antibody, which depletes CCR8+ Treg cells within the tumor microenvironment by inducing antibody-dependent cellular cytotoxicity or antibody-dependent cellular phagocytosis pathways.

                          Brand Name : SRF114

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          January 05, 2023

                          Lead Product(s) : SRF114

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SRF388, a fully human anti-IL-27 antibody designed to inhibit the activity of immunosuppressive cytokine and preclinical studies have shown that SRF388 blocks the immunosuppressive effect of IL-27, resulting in immune cell activation in combination with ...

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 07, 2022

                          Lead Product(s) : SRF388,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface has initiated a single-arm Phase 2 study evaluating SRF388 in combination with pembrolizumab in patients with NSCLC.

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 02, 2022

                          Lead Product(s) : SRF388,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine, targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks immunosuppressive biolog...

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 19, 2022

                          Lead Product(s) : SRF388

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : VIB

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Loss of IL-27 function, through either genetic deficiency or pharmacologic inhibition by SRF388, a first-in-class anti-IL-27 mAB, leads to tumor growth inhibition in mouse models and clinical data have shown monotherapy activity of SRF388 in patients wit...

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 14, 2022

                          Lead Product(s) : SRF388,Atezolizumab,Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Researchers found that IL-27 receptor signaling promoted for SRF388 in HCC development in mice, and that IL-27 served as an immunological checkpoint that regulates natural killer (NK) cell and innate immune cell activation.

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 20, 2022

                          Lead Product(s) : SRF388,Atezolizumab,Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SRF388 targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with cancer therapies includin...

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 26, 2022

                          Lead Product(s) : SRF388,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SRF388, a fully human anti-IL-27 antibody designed to inhibit activity of immunosuppressive cytokine, also targets rate-limiting p28 subunit, preclinical studies showed treatment blocks immunosuppressive biologic effects of IL-27 resulting in immune cell...

                          Brand Name : SRF388

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 27, 2022

                          Lead Product(s) : SRF388,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank